Products

Neosoma Platform
Neosoma
Clinical Decision Support & Reference
The Neosoma Platform is a cloud-based, FDA-cleared AI tool for neuro-oncology, providing automated tumor mapping, lesion tracking, and real-time insights for brain metastases and gliomas.
NS-HGlio
Neosoma
Neurology AI
Neosoma offers an FDA-cleared AI-based software platform, NS-HGlio, for semi-automatic labeling, visualization, and volumetric quantification of high-grade brain gliomas from standard MRI images, aiding in treatment planning and longitudinal assessment.
Neosoma Brain Mets
Neosoma
Neurology AI
Neosoma Brain Mets is an FDA-cleared AI-powered software for rapid MRI assessment and auto-contouring of brain metastases, providing near-real-time insights for multidisciplinary neuro-oncology teams.

See all 3 products →

About Neosoma

Neosoma is a medical technology company specializing in AI-based software for brain tumor analysis from MRI scans. The company’s cloud-native platform is designed to assist multidisciplinary neuro-oncology clinical teams, researchers, and clinical trials. It offers a portfolio of highly optimized, indication-specific software medical devices that map, measure, and track tumor compartments and lesions longitudinally, providing near real-time insights to support clinical decisions and research.

Neosoma’s technology integrates with PACS, is interoperable with radiation treatment and surgical planning systems, and is SOC2 Type II certified and HIPAA compliant. Their products, such as Neosoma Glioma and Neosoma Brain Mets, are FDA cleared. Neosoma Glioma is intended for the semi-automatic labeling, visualization, and volumetric quantification of high-grade brain glioma from standard MRI images of adult patients with pathologically proven high-grade glioma. Neosoma Brain Mets uses an AI algorithm to contour known or previously diagnosed brain tumors on MRI images for qualified medical professionals, providing precise and accurate brain tumor analysis. This technology aims to improve clinical outcomes, increase efficiency, and reduce costs in neuro-oncology.

Neosoma’s software is designed to help physicians better plan procedures, assess post-procedural results, guide treatments, track patients, and support an improved patient experience. The platform provides objective data to make treatment decisions easier and more accurate, especially for complex cases like glioblastomas, which have irregular shapes that are difficult to delineate manually. The company’s solutions are priced based on MRI volume, allowing all multidisciplinary team members to have access without incremental seat licenses.

Focus Areas

AI-based image analysis neuro-oncology brain tumor analysis medical imaging clinical decision support volumetric measurement tumor segmentation longitudinal tracking radiation treatment planning clinical trials

Business Intelligence

TechnologyCloud-native, AI-based image analysis and decision-making platform for neuro-oncology, PACS-integrated, interoperable with radiation treatment and surgical planning systems, SOC2 Type II certified, HIPAA compliant, web-based interface

What Physicians Need to Know

Specialization in Neuro-Oncology
Neosoma specializes in AI-based image analysis for neuro-oncology, focusing on brain tumor analysis, including high-grade gliomas (HGG) and brain metastases.
AI-Powered Image Analysis
Their core technology uses deep learning neural networks to automate the identification, segmentation, and volumetric measurement of brain tumors on routine MRI scans.
Clinical Decision Support
Neosoma's software provides physicians with critical insights to guide treatment decisions, plan procedures, assess post-procedural results, and track patients longitudinally.
Volumetric Measurement & Tracking
The platform offers precise and accurate 3D volumetric measurements of tumors and tracks lesions longitudinally, providing quantitative data on changes in tumor size and characteristics.
Tumor Segmentation & Radiation Treatment Planning
The AI automates Gross Tumor Volume (GTV) contouring, which is crucial for radiation treatment planning and surgical planning.
Clinical Trials & Research
Neosoma's technology supports clinical trials by providing accurate, precise, and consistent 3D longitudinal tumor measurements, addressing variability in traditional 2D measurements.
FDA Cleared Products
Neosoma has received FDA 510(k) clearance for its AI-based neuro-oncology software devices, including Neosoma HGG (High-Grade Glioma) and Neosoma Brain Mets.
Physician Tip

Neosoma's AI-powered platform provides quantitative, 3D insights into brain tumor changes, aiding in treatment planning, longitudinal tracking, and clinical decision-making. The software automates tumor segmentation and volumetric measurements, which can significantly reduce the time spent on manual assessments and enhance the application of treatment response criteria. It is designed to be a valuable complement to expert clinical judgment, providing objective data for tumor boards and patient counseling. The platform is PACS-integrated and interoperable with radiation treatment and surgical planning systems, streamlining workflows. Physicians can utilize the interactive charts, 3D/2D visualizations, and smart editing tools for comprehensive analysis and patient communication. Neosoma's technology is tolerant of real-world MRI data and does not require changes to acquisition protocols. While it offers significant efficiency and standardization, it's important to remember that the software is for informational purposes and not intended for primary diagnosis or to replace manual contouring practices.

Neosoma's cloud platform is PACS-integrated, allowing for automated sending of DICOM studies for analysis and one-click deep linking to jump from PACS to Neosoma's system. It is interoperable with various radiation treatment planning systems such as Eclipse, MIM, Gamma Plan, and Stealth, enabling easy import of lesion contours (GTVs). The platform is web-based for secure access and is SOC2 Type II certified and HIPAA compliant.

Products by Neosoma

3 products in the directory

Neosoma Platform
Neosoma
Clinical Decision Support & Reference
The Neosoma Platform is a cloud-based, FDA-cleared AI tool for neuro-oncology, providing automated tumor mapping, lesion tracking, and real-time insights for brain metastases and gliomas.
NS-HGlio
Neosoma
Neurology AI
Neosoma offers an FDA-cleared AI-based software platform, NS-HGlio, for semi-automatic labeling, visualization, and volumetric quantification of high-grade brain gliomas from standard MRI images, aiding in treatment planning and longitudinal assessment.
Neosoma Brain Mets
Neosoma
Neurology AI
Neosoma Brain Mets is an FDA-cleared AI-powered software for rapid MRI assessment and auto-contouring of brain metastases, providing near-real-time insights for multidisciplinary neuro-oncology teams.

Reviews & Opinions

No web reviews on file yet for Neosoma. Check back later for aggregated opinions from across the web.

Videos

News, demos, and interviews about Neosoma.

Loading videos...

Videos load interactively. If none appear, search YouTube for Neosoma →

View all on YouTube

Press & Coverage

Neosoma Inc.
Neosoma Announces FDA 510(k) Clearance for Neosoma HGG
Neosoma HGG, an AI-based software for three-dimensional longitudinal tumor analysis and quantification of high-grade glioma, received U.S. FDA 510(k) clearance.
2022-09
AuntMinnie.com
Neosoma nets FDA clearance for brain MRI AI software
Neosoma HGG, an AI application for assessing high-grade glioma on brain MRI exams, received FDA 510(k) clearance, performing tumor segmentation, volumetric measurements, and 3D geometric analysis.
2022-10
NJBIA
Hackensack Meridian Health Partners with Neosoma for Innovation in Brain Tumor Treatment, Research
Hackensack Meridian Health announced a strategic partnership with Neosoma to advance brain cancer treatment through AI, including clinical data sharing, research, and investment.
2023-02
Business Wire
Neosoma Expands Its Board of Directors with Debbie Millin and Frederick Driscoll
Neosoma appointed Debbie Millin and Frederick Driscoll to its board of directors, aiming to leverage their expertise for scaling software and life sciences businesses.
2023-03
Worcester Business Journal
Groton medtech firm raises $3.5M for cancer-focused AI platform
Neosoma raised $3.52 million in venture capital towards a goal of $5.8 million, with its AI software creating 3D analysis of cancerous tumors.
2026-04
Neosoma Inc.
Neosoma GmbH and Inselspital Announce Collaboration
Neosoma GmbH and Inselspital formalized and expanded their collaboration to advance oncology through AI-driven imaging analysis, focusing on brain tumors.
2025-11
AL Cancer Congress
Neosoma Receives FDA 510(k) Clearance for Brain Mets Software Medical Device
Neosoma received FDA 510(k) clearance for its Brain Mets software medical device, integrating it into its tumor analysis cloud platform for assessing brain metastases.
2025-12
Neosoma Inc.
AI-Powered Neuro-Oncology Clinical Trials
Neosoma's partnership with Calyx aims to enable faster, more precise tumor assessment in brain cancer clinical trials by providing accurate 3D longitudinal tumor measurements.
2022-11

Frequently Asked Questions

Neosoma's AI-based software, including Neosoma HGG and Neosoma Brain Mets, supports the analysis of high-grade gliomas (WHO grade 3 astrocytoma, WHO grade 4 astrocytoma, and glioblastoma) and brain metastases. Its core functionalities include automated 3D tumor segmentation, volumetric measurements, longitudinal tracking of lesions, and generating imaging for 3D geometric analysis to provide critical insights for clinical decision-making.
Neosoma's cloud platform is PACS-integrated, allowing for automated sending of DICOM studies for analysis and one-click deep linking from PACS to the Neosoma system. The platform is SOC2 Type II certified and HIPAA compliant, designed with best-in-class security practices to ensure data privacy and secure access for multidisciplinary neuro-oncology teams.
Neosoma's solution is priced based on MRI volume, allowing all multidisciplinary team members to have logins without concerns about incremental seat licenses. The platform also supports reimbursement pathways through available Category 3 CPT Codes (0865T, 0866T) for each MRI timepoint analysis.
Neosoma has strategic partnerships with Calyx to enable faster, more precise tumor assessment in brain cancer clinical trials. They also collaborate with Hackensack Meridian Health for innovation in brain tumor treatment and research, and connect to the Nuance Precision Imaging Network to broaden access to their AI solutions.
Neosoma has received U.S. Food and Drug Administration (FDA) 510(k) clearance for both its Neosoma HGG software, for high-grade glioma segmentation, and its Neosoma Brain Mets product, for the detection, tracking, and treatment planning of brain metastases. These clearances allow Neosoma to market its AI-based neuro-oncology software devices in the U.S.
Neosoma's technology provides accurate, precise, and consistent 3D longitudinal tumor measurements, which are crucial for monitoring treatment response and informing clinical decisions. The platform offers interactive charts and reports to analyze longitudinal lesion data, aiding physicians in planning procedures, assessing post-procedural results, and guiding therapies.
Founded in 2019, Neosoma is a venture capital-backed company that has raised a total of $10.2 million over five funding rounds. A recent seed round in March 2026 secured $3.52 million, indicating ongoing investment and growth in the company.

Investors

Who's funded Neosoma.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

OpenAI is an American artificial intelligence (AI) company that conducts research and develops advanced AI models. While widely known for its generative AI models like ChatGPT and DALL-E, OpenAI has significantly expanded its focus into the healthcare sector. The company’s mission is to ensure that artificial general intelligence (AGI) benefits all of humanity, and this […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]

The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.